TY  -  
T1  - Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's anti seizure efficacy 
SN  -  /  
UR  - http://hdl.handle.net/10138/312515 
T3  -  
A1  - Brandt, Claudia; Seja, Patricia; Töllner, Kathrin; Römermann, Kerstin; Hampel, Philip; Kalesse, Markus; Kipper, Andi; Feit, Peter W.; Lykke, Kasper; Toft-Bertelsen, Trine Lisberg; Paavilainen, Pauliina; Spoljaric, Inkeri; Puskarjov, Martin; MacAulay, Nanna; Kaila, Kai; Löscher, Wolfgang 
A2  -  
PB  -  
Y1  - 2018 
LA  - eng 
AB  - Based on the potential role of Na-K-Cl cotransporters (NKCCs) in epileptic seizures, the loop diuretic bumetanide, which blocks the NKCC1 isoforms NKCC1 and NKCC2, has been tested as an adjunct with phenobarbital to suppress seizures. However, because of its physicochemical properties, bumetanide only poorly penetrates through the blood-brain barrier. Thus, concentrations needed to inhibit NKCC1 in hippocampal and neocortical neurons are not reached when using doses (0.1-0.5 mg/kg) in the range ... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - Epilepsy; Anti-seizure drugs; Neonatal seizures; GABA; Giant depolarizing potentials; CATION-CHLORIDE COTRANSPORTERS; GIANT DEPOLARIZING POTENTIALS; WATER PERMEABILITY; PILOCARPINE MODEL; ANIMAL-MODELS; PYRAMIDAL NEURONS; DRUG DISCOVERY; KINDLED RATS; GABA ACTIONS; AQUAPORIN 4; 3112 Neurosciences; 1184 Genetics, developmental biology, physiology 
N1  -   
PP  -  
ER  -